AVEO Pharmaceuticals Inc (AVEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

AVEO Pharmaceuticals Inc (AVEO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH141381D
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

AVEO Pharmaceuticals Inc (AVEO) is a biopharmaceutical company which focuses on the discovery, development and commercialization of drugs for the treatment of various types of cancers. Its proprietary platform delivers insights into cancer and related diseases. AVEO develops its lead candidate tivozanib in North America as a treatment for renal cell carcinoma and other cancers. The company has strategic partnerships with EUSA, Novartis, Pharmstandard Group, Ophthotech Corporation, Biodesix Kyowa Hakko Kirin; Astellas Pharma, Biogen Idec International GmbH and others. AVEO is headquartered in Cambridge, Massachusetts, the US.

AVEO Pharmaceuticals Inc (AVEO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Aveo Pharma Amends Agreement With Biodesix For Ficlatuzumab 12

Aveo To Enter Into Co-Development Agreement For Lung Cancer Drug 14

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 15

Licensing Agreements 17

CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 17

EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 19

Novartis to Terminate Licensing Agreement with Aveo Pharma 21

AVEO Pharma Amends Licensing Agreement with St. Vincent's 22

Equity Offering 23

AVEO Pharma Prices Public Offering of Shares for USD5.7 Million 23

AVEO Pharma Raises USD6 Million in Public Offering of Shares upon Exercise of Warrants 25

AVEO Pharma Raises USD17.2 Million in Public Offering of Shares 26

Aveo Pharma Raises USD10.2 Million in Public Offering of Common Stock 27

Aveo Pharma Raises USD17 Million in Private Placement of Units 28

Aveo Pharma Completes Public Offering Of Shares For USD 57.5 Million 30

AVEO Pharmaceuticals Inc-Key Competitors 31

AVEO Pharmaceuticals Inc-Key Employees 32

AVEO Pharmaceuticals Inc-Locations And Subsidiaries 33

Head Office 33

Other Locations & Subsidiaries 33

Recent Developments 34

Financial Announcements 34

Aug 07, 2018: Aveo reports second quarter 2018 financial results and provides business update 34

May 08, 2018: AVEO Reports First Quarter 2018 Financial Results and Provides Business Update 36

Mar 13, 2018: AVEO Reports Full Year 2017 Financial Results and Provides Business Update 39

Nov 07, 2017: AVEO Reports Third Quarter 2017 Financial Results and Provides Business Update 42

Aug 09, 2017: AVEO Reports Second Quarter 2017 Financial Results and Provides Business Update 44

May 04, 2017: AVEO Reports First Quarter 2017 Financial Results and Provides Business Update 46

Mar 22, 2017: AVEO Reports Full Year 2016 Financial Results and Provides Business Update 48

Corporate Communications 50

Jun 15, 2018: AVEO Oncology added to the Russell 2000, Russell 3000, and Russell Microcap indexes 50

Nov 20, 2017: AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance 51

May 16, 2017: AVEO Oncology appoints new CFO 52

Product News 53

09/13/2017: AVEO Oncology Announces Receipt of USD 0.5 million Payment from CANbridge 53

04/03/2017: AVEO Announces Milestone Payment from CANbridge for AV-203 54

Product Approvals 55

Aug 20, 2018: Development partner Boehringer Ingelheim supplies clinical material manufactured in China for new cancer drug 55

Aug 14, 2018: AVEO announces acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) trial in esophageal squamous cell cancer (ESCC) in China 56

Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) In China 57

Clinical Trials 58

Dec 07, 2017: AVEO Oncology Announces Clinical Update on Ficlatuzumab 58

Jun 05, 2017: AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting 59

Apr 20, 2017: AVEO To Provide Update on Pipeline Drug Ficlatuzumab at 2017 ASCO Annual Meeting 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Figures

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

AVEO Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

AVEO Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Aveo Pharma Amends Agreement With Biodesix For Ficlatuzumab 12

Aveo To Enter Into Co-Development Agreement For Lung Cancer Drug 14

National Comprehensive Cancer Enters Into Co-Development Agreement With AVEO Pharma And Astellas Pharma 15

CANbridge Life Sciences Enters into Licensing Agreement with AVEO Oncology 17

EUSA Pharma Exercises Option for Licensing Agreement with AVEO Pharma for TiNivo Combination Study 19

Novartis to Terminate Licensing Agreement with Aveo Pharma 21

AVEO Pharma Amends Licensing Agreement with St. Vincent's 22

AVEO Pharma Prices Public Offering of Shares for USD5.7 Million 23

AVEO Pharma Raises USD6 Million in Public Offering of Shares upon Exercise of Warrants 25

AVEO Pharma Raises USD17.2 Million in Public Offering of Shares 26

Aveo Pharma Raises USD10.2 Million in Public Offering of Common Stock 27

Aveo Pharma Raises USD17 Million in Private Placement of Units 28

Aveo Pharma Completes Public Offering Of Shares For USD 57.5 Million 30

AVEO Pharmaceuticals Inc, Key Competitors 31

AVEO Pharmaceuticals Inc, Key Employees 32

AVEO Pharmaceuticals Inc, Subsidiaries 33

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AVEO Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com